 Eiger BioPharmaceuticals Inc NASDAQ: EIGR announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to severe illness. Peginterferon Lambda significantly reduced the risk of COVID-19-related. 